{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008865","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.766665+00:00","generated_at":"2026-06-01T06:52:09.827308+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Scholar Rock reports positive SRK-181 Phase 1 data across multiple tumors; ccRCC ORR 23.3%","bullets":["SRK-181 + pembrolizumab showed ORR 23.3% in ccRCC, 27.3% in melanoma, 18.2% in HNSCC, 9.1% in UC; no NSCLC response.","Safety manageable: no Grade 5 AEs; most common AEs were rash, pruritus, fatigue; one Grade 4 dermatitis exfoliative.","Biomarker analysis in ccRCC: baseline CD8+ infiltration doubled ORR to 40%; elevated Treg levels raised ORR to 50%.","Company plans end of Phase 1 meeting with FDA and evaluating partnership opportunities for SRK-181."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008865","json":"https://secwatch.observer/filing/0001558370-24-008865.json","markdown":"https://secwatch.observer/filing/0001558370-24-008865.md","text":"https://secwatch.observer/filing/0001558370-24-008865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024008865/0001558370-24-008865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024008865/srrk-20240603x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:52:09.827308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}